girk

SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective dopamine D1-like receptor antagonist, specifically targeting D1 and D5 receptors with Ki values of 0.2 nM and 0.3 nM, respectively.

ML 297 is a selective Kir3.1/3.2 (GIRK1/2) channel activator (IC50 values are 160, 887 and 914 nM for GIRK1/2, GIRK1/4 and GIRK1/3 respectively). ML 297 exhibits no effect on GIRK2, GIRK2/3, Kir2.1 and Kv7.4 channels, and has minimal effect on a panel of other ion channels, receptors and transporters.

VU0810464 is a non-ureaG protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) activator.

SCH-23390 hydrochloride (R-(+)-SCH23390 hydrochloride) is an effective dopamine receptor antagonist, with high affinity for the D1 (Ki=0.2 nM) and D5 (Ki=0.3 nM) receptors.

VU0529331 is a modestly selective non-GIRK1-containing G protein-gated, inwardly-rectifying, potassium channel activator (EC50s: 5.1 μM and 5.2 μM for GIRK2 and GIRK1/2 in HEK293 cells, respectively), and is also effective on the GIRK4 homomeric channel.

Ifenprodil is a selective NMDA receptor (glutamate) antagonist.

Ifenprodil (RC61-91) is an inhibitor of the NMDA receptor, specifically of GluN1 (glycine-binding NMDA receptor subunit 1) and GluN2B (glutamate-binding NMDA receptor subunit 2) subunits. Additionally, Ifenprodil inhibits GIRK channels and interacts with alpha1 adrenergic, serotonin, and sigma receptors.

Tipepidine hydrochloride is a reversible inhibitor of dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) (IC50: 7.0 μM), with antidepressant-like effect.

AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G protein-coupled inwardly-rectifying potassium channels (GIRK) through binding to CB1 and CB2 receptors, demonstrating significant cannabinoid-like activity. Its EC50 values are 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be applicable for research in pain management, neurodegenerative diseases, and inflammation-related mechanisms.

AB-ICA is a precursor to AB-FUBICA. AB-FUBICA (Compound 13) acts as an agonist for the CB1 and CB2 receptors, demonstrating significant cannabinoid-like activity by activating G protein-coupled inwardly-rectifying potassium channels (GIRK) through binding with these receptors.

CNV-dopamine is a photoactivatable, selective agonist of the D2 receptor (D2 receptor). It activates the D2 receptor, triggering G protein-coupled inwardly rectifying potassium (GIRK) currents. CNV-dopamine shows potential for research in diseases such as Parkinson's disease and addiction.

Tipepidine is a non-narcotic antitussive with an antidepressant-like effect. Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK) ) (IC 50 = 7.0 μM) and subsequently activates VTA dopamine neurons.